Skip to content

Clinical trials

Breast Neoplasms trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Country / region: France Clear all

1,122 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
200112
200212
200316
200422
200521
200641
200738
200844
200937
201040
201146
201242
201343
201452
201560
201649
201746
201852
201954
202051
202167
202256
202349
202453
202557
202637

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed618
Recruiting146
Terminated127
Active, not recruiting109
Unknown status84
Not yet recruiting20
Withdrawn14
Approved for marketing2
Enrolling by invitation1
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche65
Novartis Pharmaceuticals52
UNICANCER52
Institut du Cancer de Montpellier - Val d'Aurelle42
AstraZeneca39
Centre Oscar Lambret35
Institut Curie31
Eli Lilly and Company28
Hospices Civils de Lyon28
Institut Cancerologie de l'Ouest27

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms1,122
Neoplasm Metastasis95
Neoplasms82
Lung Neoplasms48
Ovarian Neoplasms41
Colorectal Neoplasms40
Prostatic Neoplasms39
Triple Negative Breast Neoplasms36
Carcinoma, Non-Small-Cell Lung34
Colonic Neoplasms23

Trials

Showing 51 to 75 of 1,122. Each trial links to its page on Pharma Observatory.

1,022 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.